ライフサイエンスコーパス: Pneumocystis carinii

1 A variety of genes have been used to type Pneumocystis carinii.

2 coccus neoformans, five Candida species, and Pneumocystis carinii.

3 IDS-associated opportunistic fungal pathogen Pneumocystis carinii.

4 inst DHFR from human, Toxoplasma gondii, and Pneumocystis carinii.

5 mice deficient in IL-12 after inoculation of Pneumocystis carinii.

6 nistic pathogens such as Cryptosporidium and Pneumocystis carinii.

7 e to the major surface glycoprotein (MSG) of Pneumocystis carinii.

8 on the surface of the opportunistic pathogen Pneumocystis carinii.

9 odes the major surface glycoprotein (MSG) of Pneumocystis carinii.

10 Models were created for DHFR from human and Pneumocystis carinii.

11 roteins in the opportunistic fungal pathogen Pneumocystis carinii.

12 tor, and prophylaxis for cytomegalovirus and Pneumocystis carinii.

13 ome map of the AIDS-related fungal pathogen, Pneumocystis carinii.

14 oup I intron from the opportunistic pathogen Pneumocystis carinii.

15 Innate immune mechanisms against Pneumocystis carinii, a frequent cause of pneumonia in i

16 The major surface glycoprotein (MSG) of Pneumocystis carinii, a pathogen responsible for pulmona

17 rtant role in pulmonary host defense against Pneumocystis carinii, an important pathogen in individua

18 ximab was associated with inhibition of anti-Pneumocystis carinii and anti-Candida albicans antibody

19 odels and displayed in vivo activity against Pneumocystis carinii and C. albicans.

20 DNA-binding properties and activity against Pneumocystis carinii and Cryptosporidium parvum infectio

21 munity, mediates binding and phagocytosis of Pneumocystis carinii and likely represents an important

22 f the collectin family, selectively binds to Pneumocystis carinii and mediates interactions between p

23 the thioredoxin reductase (trr1) genes from Pneumocystis carinii and Pneumocystis jiroveci, and have

24 his organism and its closely related species Pneumocystis carinii and Pneumocystis murina by a combin

25 We have characterized rad51 of Pneumocystis carinii and Pneumocystis murina.

26 done for the other enigmatic human pathogens Pneumocystis carinii and Rhinosporidium seeberi, we ampl

27 addition, compound 5 inhibited the growth of Pneumocystis carinii and Toxoplasma gondii cells in cult

28 were synthesized as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate

29 All patients received prophylaxis against Pneumocystis carinii and varicella zoster.

30 ich causes Pneumocystis pneumonia in humans, Pneumocystis carinii, and Pneumocystis murina, beta-1,3-

31 ydrofolate reductase enzymes from T. gondii, Pneumocystis carinii, and rat liver.

32 Mice immunized with recombinant mouse Pneumocystis carinii antigen A12-thioredoxin fusion prot

33 To examine the repertoire of Pneumocystis carinii antigens recognized by antibody-sec

34 Host defense mechanisms against Pneumocystis carinii are not fully understood.

35 d dams were given intranasal inoculations of Pneumocystis carinii as neonates (24 to 48 h old).

36 Therefore, we studied the role of Pneumocystis carinii, as well as Saccharomyces cerevisia

37 nce of cytomegalovirus infection or disease, Pneumocystis carinii, Aspergillus, or other fungal infec

38 recently reported that the pathogenic fungus Pneumocystis carinii assembles a beta-glucan-rich cell w

39 In the fungus Pneumocystis carinii, at least three gene families (PRT1

40 osomal RNA group I intron from mouse-derived Pneumocystis carinii binds to a ribozyme that is a trunc

41 ron ribozyme from the opportunistic pathogen Pneumocystis carinii by 1,000- to 100,000-fold relative

42 ype control mice (SP-A(+/+)) were exposed to Pneumocystis carinii by environmental exposure, intratra

43 l location were examined for the presence of Pneumocystis carinii by screening for P. carinii-specifi

44 ved ribozyme from the opportunistic pathogen Pneumocystis carinii can bind an RNA in trans and excise

45 ved ribozyme from the opportunistic pathogen Pneumocystis carinii catalyzes the excision of a predefi

46 Pneumocystis carinii causes pneumonitis in immunodeficie

47 Pneumocystis carinii causes severe pneumonia in immunoco

48 to visualize melanin-like components of the Pneumocystis carinii cell wall.

49 onse in immunocompetent (IC) hosts following Pneumocystis carinii challenge.

50 changes were greatest in animals with clear Pneumocystis carinii coinfection.

51 rs have reported that patients infected with Pneumocystis carinii containing mutations in the DHPS (d

52 ort study was conducted to determine whether Pneumocystis carinii cytochrome b gene mutations in pati

53 Effective host defense against Pneumocystis carinii depends upon the integrated actions

54 These compounds were poor inhibitors of Pneumocystis carinii DHFR and rat liver DHFR.

55 me inhibition assays against rat liver DHFR, Pneumocystis carinii DHFR, and the bifunctional DHFR-TS

56 a (TAB), a potent and selective inhibitor of Pneumocystis carinii DHFR, was selected as the starting

57 were synthesized as potential inhibitors of Pneumocystis carinii dihydrofolate reductase (pcDHFR) an

58 he oxidized coenzyme, NADP+, and recombinant Pneumocystis carinii dihydrofolate reductase (pcDHFR) re

59 uestion mark-6-ethylpyrimidine] (TAB, 1) and Pneumocystis carinii dihydrofolate reductase (pcDHFR), r

60 In the opportunistic pathogen Pneumocystis carinii, dihydroneopterin aldolase function

61 ine factors associated with mutations in the Pneumocystis carinii dihydropteroate synthase (DHPS) gen

62 Recent studies of the human Pneumocystis carinii dihydropteroate synthase (DHPS) gen

63 Mutations in the human-derived Pneumocystis carinii dihydropteroate synthase (DHPS) gen

64 This study of Pneumocystis carinii dihydropteroate synthase (DHPS) mut

65 Although PCR detection of Pneumocystis carinii DNA has been described, little is k

66 his study was conducted to determine whether Pneumocystis carinii dyhydropteroate synthase (DHPS) gen

67 Pneumocystis carinii expresses a surface glycoprotein ca

68 A Pneumocystis carinii extracellular signal-regulated prot

69 Pneumocystis carinii f. sp. carinii IMPDH mRNA (GeneBank

70 The major surface glycoprotein (MSG) of Pneumocystis carinii f. sp. carinii is a family of prote

71 thin the mitochondrial large-subunit rRNA of Pneumocystis carinii f. sp. carinii.

72 regions of the rRNA genes were used to type Pneumocystis carinii f. sp. hominis DNA obtained from th

73 Pneumocystis carinii f. sp. hominis isolates from 207 cl

74 of the internal transcribed spacer (ITS) of Pneumocystis carinii f. sp. hominis strains from 7 of 15

75 o determine the copy number of rRNA genes in Pneumocystis carinii f. sp. hominis.

76 Clearance of Pneumocystis carinii f. sp. muris (PC) organisms from th

77 ficient mice are susceptible to infection by Pneumocystis carinii f. sp. muris (PC).

78 y using mouse models, it has been shown that Pneumocystis carinii f. sp. muris can be transmitted to

79 this study was to determine the kinetics of Pneumocystis carinii f. sp. muris infection in adult imm

80 ase chain reaction assay for quantitation of Pneumocystis carinii f. sp. muris.

81 Pneumocystis carinii forma specialis carinii has a uniqu

82 formance of a PCR assay for the detection of Pneumocystis carinii from respiratory specimens that has

83 r cells largely responsible for clearance of Pneumocystis carinii from the lungs.

84 Using the Pneumocystis carinii Genome Project database, two partia

85 target selection in the human, C.elegans and Pneumocystis carinii genomes.

86 ion-splicing (TES) ribozymes, derived from a Pneumocystis carinii group I intron, can catalyze the ex

87 ate in vitro that a ribozyme, derived from a Pneumocystis carinii group I intron, can replace the 5'

88 In the trans excision-splicing reaction, a Pneumocystis carinii group I intron-derived ribozyme bin

89 Continuous axenic culture of Pneumocystis carinii has been achieved.

90 Pneumonia due to Pneumocystis carinii has been increasingly reported in p

91 large ribosomal subunit RNA of mouse-derived Pneumocystis carinii has been isolated and characterized

92 A group I intron-derived ribozyme from Pneumocystis carinii has been previously shown to bind a

93 Pneumocystis carinii has been recognized as a human path

94 Pneumocystis carinii has been shown to cause extra-alveo

95 Immunization with whole Pneumocystis carinii has been shown to protect mice from

96 It is well established that Pneumocystis carinii has the molecular capability for va

97 Prior studies in Pneumocystis carinii have characterized beta-1,3 glucan

98 ntly have been reported to be active against Pneumocystis carinii in cell culture.

99 been the standard procedure for detection of Pneumocystis carinii in commercial rat colonies.

100 cruzi, Leishmania mexicana amazonensis, and Pneumocystis carinii in culture.

101 A method for reliable quantification of Pneumocystis carinii in research models of P. carinii pn

102 oides brasiliensis can resemble the cysts of Pneumocystis carinii in smears stained with Grocott's mo

103 S-adenosylmethionine (AdoMet) is required by Pneumocystis carinii in vitro, Pneumocystis infection de

104 Unlike the case for Pneumocystis carinii, in which the homologous PRT-1 gene

105 Differences in gene expression between Pneumocystis carinii-infected and noninfected rats were

106 Alveolar macrophages from Pneumocystis carinii-infected hosts are defective in pha

107 Expression screening of a Pneumocystis carinii-infected mouse lung cDNA library wi

108 Alveolar macrophages from Pneumocystis carinii-infected rats are defective in phag

109 TCR(+)) CD4(+) T cells and susceptibility to Pneumocystis carinii infection exists, the role of other

110 To facilitate studies of Pneumocystis carinii infection in humans, we undertook t

111 To establish experimental Pneumocystis carinii infection in simian immunodeficienc

112 Host responses to Pneumocystis carinii infection mediate impairment of pul

113 ), and CD40L-deficient mice with spontaneous Pneumocystis carinii infection.

114 and B cells are critical for defense against Pneumocystis carinii infection; however, the mechanism b

115 neic bone marrow transplants along with lung Pneumocystis carinii infections and were treated with ei

116 10 mice grafted with FP THY/LIV also cleared Pneumocystis carinii infections, whereas simultaneously-

117 c infections, such as Mycobacterium avium or Pneumocystis carinii infections.

118 However, all mice that received both WBI and Pneumocystis carinii inoculation developed a more protra

119 Pneumocystis carinii is a common cause of life-threateni

120 Pneumocystis carinii is a family of organisms found in a

121 Pneumocystis carinii is a mammalian pathogen that contai

122 Pneumocystis carinii is a mammalian pathogen that infect

123 Pneumocystis carinii is an ascomycete phylogenetically r

124 Pneumocystis carinii is an important pulmonary pathogen

125 Pneumocystis carinii is an opportunistic fungal pathogen

126 Pneumocystis carinii is an opportunistic fungal pathogen

127 Pneumocystis carinii is an opportunistic fungal pathogen

128 Pneumocystis carinii is an opportunistic fungal pathogen

129 Pneumocystis carinii is an opportunistic fungal pathogen

130 Pneumocystis carinii is an opportunistic fungus causing

131 on of the pulmonary inflammatory response to Pneumocystis carinii is delayed by 3 wk in mice infected

132 gate whether successful host defense against Pneumocystis carinii is dependent on induction of induci

133 The means by which humans acquire Pneumocystis carinii is not well understood.

134 and clearance of the opportunistic pathogen Pneumocystis carinii is poorly understood.

135 Prophylaxis for herpes virus and Pneumocystis carinii is standard with this agent.

136 intron in the mouse-derived fungal pathogen Pneumocystis carinii is the docking site for the first s

137 Pneumocystis carinii is the most common lethal opportuni

138 Pneumocystis carinii is unable to synthesise S-adenosylm

139 biosynthesis kinase gene (CBK1) homologue in Pneumocystis carinii, isolated by differential display P

140 RNA genes were found to be useful for typing Pneumocystis carinii isolates that infect humans.

141 Pneumocystis carinii lipids are similar to host lipids,

142 wn for Mycobacterium avium complex (MAC) and Pneumocystis carinii, macrophages infected with opportun

143 in the expression site of the human-derived Pneumocystis carinii major surface glycoprotein gene was

144 Th1) or Th2 responses are protective against Pneumocystis carinii, mice with disrupted interleukin 4

145 ated with opportunistic infections caused by Pneumocystis carinii, Mycobacterium avium, and Campyloba

146 Among HIV-positive patients, Pneumocystis carinii, Mycobacterium tuberculosis, S. pne

147 4 persons with active lung disease caused by Pneumocystis carinii (n = 26), bacteria (n = 3), Mycobac

148 a self-splicing group I intron derived from Pneumocystis carinii or from bacteriophage T4 have been

149 more effective than pentamidine against the Pneumocystis carinii pathogen in an immunosuppressed rat

150 Recombinant DHFR from Pneumocystis carinii (pc) and native DHFR from Toxoplasm

151 rimidines 5-17 were synthesized as potential Pneumocystis carinii (pc) and Toxoplasma gondii (tg) dih

152 e synthesized and evaluated as inhibitors of Pneumocystis carinii (pc) and Toxoplasma gondii (tg) dih

153 itors of dihydrofolate reductase (DHFR) from Pneumocystis carinii (pc) and Toxoplasma gondii (tg) org

154 ds were evaluated as inhibitors of DHFR from Pneumocystis carinii (pc) and Toxoplasma gondii (tg) wit

155 stic infections in patients with AIDS, i.e., Pneumocystis carinii (pc) and Toxoplasma gondii (tg).

156 Pneumocystis carinii (Pc) beta-glucans are major compone

157 ) models for the inhibitory activity against Pneumocystis carinii (pc) DHFR, Toxoplasma gondii (tg) D

158 feasibility of mucosal immunization against Pneumocystis carinii (Pc) experimental infection, female

159 elayed CD4-mediated inflammatory response to Pneumocystis carinii (PC) infection in the lungs that co

160 inhibition from pathogenic organisms such as Pneumocystis carinii (pc) or Pneumocystis jirovecii (pj)

161 Pneumocystis carinii (PC) pneumonia is a leading opportu

162 ach to a prototypic AIDS-defining infection, Pneumocystis carinii (PC) pneumonia.

163 common HIV-related opportunistic infection, Pneumocystis carinii (PC) pneumonia.

164 A hallmark of HIV infection is Pneumocystis carinii (PC) pneumonia.

165 s promotes respiratory failure during severe Pneumocystis carinii (PC) pneumonia.

166 The opportunistic organism Pneumocystis carinii (Pc) produces a life-threatening pn

167 Phe69 of dihydrofolate reductase (DHFR) from Pneumocystis carinii (pc) to afford selective inhibitors

168 ogues were tested as inhibitors of DHFR from Pneumocystis carinii (Pc), Toxoplasma gondii (Tg), and M

169 itors of dihydrofolate reductase (DHFR) from Pneumocystis carinii (Pc), Toxoplasma gondii (Tg), and M

170 itors of dihydrofolate reductase (DHFR) from Pneumocystis carinii (Pc), Toxoplasma gondii (Tg), and M

171 Compounds 2-8 and 10 were evaluated against Pneumocystis carinii (pc), Toxoplasma gondii (tg), and r

172 e synthesized and evaluated as inhibitors of Pneumocystis carinii (pc), Toxoplasma gondii (tg), and r

173 purified dihydrofolate reductase (DHFR) from Pneumocystis carinii (Pc), Toxoplasma gondii (Tg), Mycob

174 ecules in the fungal opportunistic pathogen, Pneumocystis carinii (PcADAM).

175 tested for the ability to inhibit DHFR from Pneumocystis carinii (pcDHFR), Toxoplasma gondii (tgDHFR

176 famethoxazole (TMP-SMX) was incorporated for Pneumocystis carinii (PCP) prophylaxis.

177 tative touch-down (QTD) real-time diagnostic Pneumocystis carinii PCR assay with an associated intern

178 Thymidylate synthase from Pneumocystis carinii (PcTS) is an especially important d

179 The cocrystal structure of TS from Pneumocystis carinii (PcTS), a new drug target for an im

180 ith the mannose receptor, including impaired Pneumocystis carinii phagocytosis and mannosylated album

181 %; OR, 4.9; 95% CI, 1.0-24), and to have had Pneumocystis carinii pneumonia (52.9% vs. 11.8%; OR, 7.6

182 84%), Mycobacterium avium complex (73%), and Pneumocystis carinii pneumonia (69%), and the positive p

183 Pneumocystis carinii pneumonia (OR = 0.24, p = 0.001), m

184 To examine survival after diagnosis of Pneumocystis carinii pneumonia (PCP) and factors associa

185 The epidemiology of Pneumocystis carinii pneumonia (PCP) and its geographic

186 h human immunodeficiency virus (HIV)-related Pneumocystis carinii pneumonia (PCP) and respiratory fai

187 Pneumocystis carinii pneumonia (PCP) can be diagnosed by

188 The clinical severity of Pneumocystis carinii pneumonia (PCP) correlates closely

189 With decreasing incidence of pneumocystis carinii pneumonia (PCP) in AIDS as a result

190 ons and their evaluation as prodrugs against Pneumocystis carinii pneumonia (PCP) in an immunosuppres

191 ination with sulphonamides is active against Pneumocystis carinii pneumonia (PCP) in animals.

192 The prevalence of Pneumocystis carinii pneumonia (PCP) in humans caused by

193 During Pneumocystis carinii pneumonia (PCP) in mice, the degree

194 Pneumocystis carinii pneumonia (PcP) is a clinically imp

195 Necropsy studies from Africa have shown that Pneumocystis carinii pneumonia (PCP) is common in infant

196 amethoxazole (TMP-SMZ) is the most effective Pneumocystis carinii pneumonia (PCP) prophylactic agent,

197 Pneumocystis carinii pneumonia (PCP) remains a major cau

198 Pneumocystis carinii pneumonia (PcP) remains among the m

199 Pneumocystis carinii pneumonia (PCP) remains the most co

200 Despite recent declines in incidence, Pneumocystis carinii pneumonia (PCP) remains the most co

201 rs for the development of a first episode of Pneumocystis carinii pneumonia (PCP) were investigated i

202 e Mycobacterium avium complex (MAC) disease, Pneumocystis carinii pneumonia (PCP), and cytomegaloviru

203 ociated respiratory infections, most notably Pneumocystis carinii pneumonia (PCP), but also bacterial

204 principal diagnosis of lung disease; 11 had Pneumocystis carinii pneumonia (PCP), one of whom was co

205 en shown to contribute to lung injury during Pneumocystis carinii pneumonia (PCP), there are conflict

206 e in pulmonary damage and dysfunction during Pneumocystis carinii pneumonia (PcP).

207 able to discontinue chemoprophylaxis against Pneumocystis carinii pneumonia (PCP).

208 unodeficiency virus (HIV) infection has been Pneumocystis carinii pneumonia (PCP).

209 tovaquone in the prevention and treatment of Pneumocystis carinii pneumonia (PCP).

210 There were 145 episodes of Pneumocystis carinii pneumonia (PCP).

211 provide a new method for rapid diagnosis of Pneumocystis carinii pneumonia (PCP).

212 for community-acquired pneumonia, including Pneumocystis carinii pneumonia (PCP; patients), and 192

213 gory (RR2.0, 95% CI 1.43 to 2.76), and prior Pneumocystis carinii pneumonia (RR 3.88, 95% CI 1.65 to

214 lnesses (primary outcome) and, specifically, Pneumocystis carinii pneumonia (secondary outcome).

215 sk for preventable opportunistic infections (Pneumocystis carinii pneumonia [PCP] and disseminated My

216 unistic infections occurred in 3 patients: 2 Pneumocystis carinii pneumonia and 1 cytomegalovirus ret

217 variables have been studied in patients with Pneumocystis carinii pneumonia and acquired immunodefici

218 admission electrocardiogram in patients with Pneumocystis carinii pneumonia and AIDS in an attempt to

219 tive care should include prophylaxis against Pneumocystis carinii pneumonia and esophageal candidiasi

220 aking corticosteroids are at greater risk of Pneumocystis carinii pneumonia and may benefit from prop

221 tiretroviral therapy and prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis).

222 Although the clinical aspects of Pneumocystis carinii pneumonia are well characterized, t

223 t whether there was geographic clustering of Pneumocystis carinii pneumonia cases among patients with

224 Pneumocystis carinii pneumonia did not develop in either

225 99 cells/mm3, the incidence of bacterial and Pneumocystis carinii pneumonia each increased an average

226 ly trends in survival after the diagnosis of Pneumocystis carinii pneumonia for 19,607 patients in Ca

227 Pneumocystis carinii pneumonia has decreased substantial

228 of the new compounds were effective against Pneumocystis carinii pneumonia in the immunosuppressed r

229 Pneumocystis carinii pneumonia is a hallmark disease ass

230 Pneumocystis carinii pneumonia is also common in this se

231 Pneumocystis carinii pneumonia is an important cause of

232 Pneumocystis carinii pneumonia is associated with a high

233 ulfamethoxazole (TMP-SMX) is widely used for Pneumocystis carinii pneumonia prophylaxis in human immu

234 Pneumocystis carinii pneumonia remains a serious complic

235 concentrations to treat severe cases of the Pneumocystis carinii pneumonia typical of HIV infection.

236 The role of SP-D in host defense against Pneumocystis carinii pneumonia was assessed using SP-D k

237 Pneumocystis carinii pneumonia was diagnosed in one and

238 Pneumocystis carinii pneumonia was reported in two patie

239 A 49-year-old male with Pneumocystis carinii pneumonia was seen at Bellevue Hosp

240 laria, toxoplasmosis, cryptosporidiosis, and Pneumocystis carinii pneumonia).

241 cy causes recurrent sinopulmonary infection, Pneumocystis carinii pneumonia, and Cryptosporidium parv

242 secondary transplanted mice, attenuation of Pneumocystis carinii pneumonia, and no evidence of lymph

243 ally to treat Plasmodium falciparum malaria, Pneumocystis carinii pneumonia, and Toxoplasma gondii to

244 d Enterobacter cloacae, Serratia marcescens, Pneumocystis carinii pneumonia, and unknown (7%, 1 of 15

245 of < 50 cells/microL and was associated with Pneumocystis carinii pneumonia, cytomegalovirus meningoe

246 of lymphopenia, and included single cases of Pneumocystis carinii pneumonia, disseminated varicella z

247 was not helpful in other diseases including Pneumocystis carinii pneumonia, infection with Cryptococ

248 is the drug of choice for the prevention of Pneumocystis carinii pneumonia, many patients cannot tol

249 any of three major opportunistic infections (Pneumocystis carinii pneumonia, Mycobacterium avium comp

250 Using a SCID mouse model of Pneumocystis carinii pneumonia, we were able to demonstr

251 ycardia and right heart strain are common in Pneumocystis carinii pneumonia.

252 now a more frequent cause of admission than Pneumocystis carinii pneumonia.

253 substantially to respiratory failure during Pneumocystis carinii pneumonia.

254 functional lymphocytes and therefore develop Pneumocystis carinii pneumonia.

255 n = 6), including 2 patients who died of non-Pneumocystis carinii pneumonia.

256 ely used in the treatment and prophylaxis of Pneumocystis carinii pneumonia.

257 corticosteroid-immunosuppressed rat model of Pneumocystis carinii pneumonia.

258 tible to opportunistic infections, including Pneumocystis carinii pneumonia.

259 seful in predicting outcome in patients with Pneumocystis carinii pneumonia.

260 ith those of dexamethasone in provocation of Pneumocystis carinii pneumonitis in virus-free Sprague-D

261 y that recognized Pneumocystis jirovecii and Pneumocystis carinii Potential orthologs of Pca1 have be

262 n immunizations, this article also discusses Pneumocystis carinii prophylaxis in immunosuppressed pat

263 Pneumocystis carinii prophylaxis was required.

264 ctive prophylaxis, infection with the fungus Pneumocystis carinii remains a common cause of respirato

265 Pneumocystis carinii remains a persistent cause of sever

266 Pneumocystis carinii remains an important and potentiall

267 Pneumocystis carinii remains an important cause of pneum

268 Pneumocystis carinii remains an important opportunistic

269 the molecules involved in the regulation of Pneumocystis carinii replication and development in vitr

270 t defense against the opportunistic pathogen Pneumocystis carinii requires functional interactions of

271 natal mice with an intranasal inoculation of Pneumocystis carinii results in a subclinical infection

272 tyrosine enzyme from the eukaryote pathogen Pneumocystis carinii showed just the opposite species sp

273 wed by Aspergillus species (seven episodes), Pneumocystis carinii (six episodes), herpes simplex viru

274 f the PRT1 protease of the pathogenic fungus Pneumocystis carinii sp. f. carinii, encoded by a subtel

275 eroate synthase (DHPS) genes among different Pneumocystis carinii strains, these 2 genes in P. carini

276 evaluated as inhibitors of DHFR from human, Pneumocystis carinii, T. gondii, rat liver, Lactobacillu

277 rophages participate in host defense against Pneumocystis carinii, their role in organism degradation

278 f the AIDS-associated opportunistic pathogen Pneumocystis carinii to diminish 15 times more rapidly t

279 nstituted scid mice, we used mouse models of Pneumocystis carinii to investigate the role of regulato

280 raction of the opportunistic fungal pathogen Pneumocystis carinii to lung epithelial cells and extrac

281 l moiety were synthesized and tested against Pneumocystis carinii, Toxoplasma gondii, and Mycobacteri

282 ibitors of the reduction of dihydrofolate by Pneumocystis carinii, Toxoplasma gondii, and rat liver D

283 oprim (TMP) and were tested as inhibitors of Pneumocystis carinii, Toxoplasma gondii, and rat liver d

284 oderate inhibitory potency against DHFR from Pneumocystis carinii, Toxoplasma gondii, Mycobacterium a

285 nst DHFR from six sources (human, rat liver, Pneumocystis carinii, Toxoplasma gondii, Mycobacterium a

286 novel inhibitor with a Ki of 310 nM against Pneumocystis carinii TS.

287 mere and adjacent sequences from rat-derived Pneumocystis carinii using the ability of foreign telome

288 cer (ITS) regions of the rRNA genes of human Pneumocystis carinii was developed.

289 ds against the immunosuppressed rat model of Pneumocystis carinii was evaluated.

290 ds against the immunosuppressed rat model of Pneumocystis carinii was evaluated.

291 ma interferon (IFN-gamma) in host defense to Pneumocystis carinii was investigated by use of three di

292 +) T lymphocytes to the lungs in response to Pneumocystis carinii was investigated.

293 a group I intron ribozyme from mouse-derived Pneumocystis carinii was measured for the hexamers, r(AU

294 vestigate the functions of Asf1 and Vps75 in Pneumocystis carinii, we cloned and characterized both o

295 In the opportunistic fungus Pneumocystis carinii, we have identified a protein conta

296 The specific activities in untreated Pneumocystis carinii were 1.78 +/- 0.5 pmol min(-1) mg p

297 Gram-negative bacilli, cytomegalovirus, and Pneumocystis carinii were the usual pulmonary pathogens

298 ease such as Mycobacterium avium complex and Pneumocystis carinii, were identified as highly producti

299 epron, 566c80) is an effective agent against Pneumocystis carinii, which probably acts by binding to

300 host species-specific antigenic variation of Pneumocystis carinii would affect immune recognition, mi